Chronic kidney disease

Chronic kidney disease is a major renal consequence associated with hepatitis C virus infection, extending the disease beyond the liver into proteinuria, glomerular injury, impaired filtration, and end-stage renal disease. Its significance lies not only in the increased frequency of kidney abnormalities among HCV-positive people, but also in the shorter time to CKD, the special vulnerability of patients receiving hemodialysis, and the additional risks faced by kidney transplant recipients.

Definition and Clinical Scope

Chronic kidney disease is discussed in the evidence through persistent proteinuria, hematuria, reduced estimated glomerular filtration rate, or progression to end-stage renal disease. In HCV-positive populations, kidney injury may occur with or without significant liver disease, but patients with HCV-associated glomerulonephritis are consistently HCV RNA-positive in serum. This distinction prevents a positive antibody result from being treated as proof of active renal-relevant infection: anti-HCV antibodies identify exposure, whereas detectable HCV RNA establishes current infection.

The broader medical framework treats HCV as a systemic disease rather than an isolated hepatic disorder. It can produce renal, autoimmune, and dermatologic disease, and this connection led Kidney Disease Improving Global Outcomes to make HCV an important subject in nephrology, dialysis, and transplantation. The resulting clinical-practice guideline became a central reference for preventing, diagnosing, evaluating, and treating HCV in people with CKD.

HCV and Risk of Kidney Disease

Epidemiologic evidence consistently associates HCV with a greater risk of CKD. In a United States study of 18,002 people with HCV infection and 25,137 controls who had an estimated glomerular filtration rate above 60 ml/min/1.73 m2 at baseline, HCV infection was associated with a higher risk of developing CKD stages 3–5. Older age, hypertension, and diabetes increased risk in both groups, while decompensated liver disease strongly predicted CKD. HCV-positive patients nevertheless reached CKD in a shorter time.

A second comparison of 552 anti-HCV-positive patients with 313 HCV-negative patients defined CKD as an estimated glomerular filtration rate below 60 ml/min/1.73 m2 and/or proteinuria persisting for more than six months. CKD prevalence was 9.6% among HCV-positive patients versus 5.1% among those without HCV. The HCV-positive group also developed CKD and end-stage renal disease more rapidly, and a higher baseline viral load independently predicted CKD. These findings connect renal risk not merely with historical exposure but with the burden of ongoing viral infection.

Other population studies refine rather than erase this association. In NHANES III, HCV seropositivity was associated with albuminuria in an age-dependent manner: the adjusted odds ratio was 1.84 among people aged 40–59 years and 1.27 among those aged at least 60 years. In the older group, 46% of HCV-positive individuals had albuminuria, compared with 24% of HCV-antibody-negative individuals, although no significant association with low estimated filtration rate was found. In Taiwan, non-diabetic anti-HCV-positive patients had proteinuria more often than seronegative patients, 8.3% versus 5.1%, and HCV status remained associated with proteinuria after multivariable adjustment.

The magnitude of risk varies geographically and clinically. In 320 predialysis patients in Italy, HCV infection occurred in 6.25%, far above the expected European range of 0.2–3.5%. By contrast, a Norwegian prospective cohort of 1,010 HCV-positive patients diagnosed between 1990 and 2000 found renal failure caused by membranoproliferative glomerulonephritis in 0.2%. Taken together, these observations support HCV as a risk factor for proteinuria and impaired renal function without implying that every HCV-positive patient develops advanced renal disease.

Glomerular Disease and Diagnosis

The most frequent HCV-associated renal lesion is type I membranoproliferative glomerulonephritis associated with type II mixed cryoglobulinemia. Non-cryoglobulinemic membranoproliferative glomerulonephritis and membranous glomerulonephritis are reported less often. The prevalence of HCV seropositivity in case series of membranoproliferative glomerulonephritis has been reported as approximately ten times higher than in HCV-negative patients, reinforcing the epidemiologic and pathologic connection.

The usual clinical signals are proteinuria and microscopic hematuria, with or without impaired kidney function. Mixed cryoglobulinemia may add arthralgias, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and positive rheumatoid factor. Kidney involvement can appear as non-nephrotic or nephrotic proteinuria, hematuria, or reduced filtration; acute nephritic syndrome occurs in about 25% of affected patients and nephrotic syndrome in about 20%. Purpura, joint symptoms, or neuropathy may precede renal disease by several years.

Because renal injury can be clinically silent, international guidance recommends at least annual testing of HCV-infected patients for proteinuria, hematuria, and estimated glomerular filtration rate, with particular attention to patients who have cryoglobulinemia. A kidney biopsy is recommended when there is clinical evidence of glomerulonephritis, because early recognition and treatment of HCV-associated renal disease may improve outcomes.

Diagnosis must also establish whether HCV is active. Third-generation enzyme-linked immunosorbent assays detect anti-HCV antibodies, but they cannot by themselves separate resolved infection from chronic infection. Sensitive molecular assays detect serum HCV RNA, with a threshold of approximately 15 IU/ml; chronic infection requires both anti-HCV positivity and HCV RNA positivity persisting for more than six months. Assessment of active disease includes hepatic as well as extrahepatic effects. Liver biopsy can stage and grade injury, while biochemical and morphologic tools, including FibroScan measurement of liver stiffness, can reduce the need for biopsy and permit yearly fibrosis follow-up.

Dialysis and Transplantation Contexts

The association between HCV and CKD is intensified by renal replacement therapy. Hemodialysis patients were recognized as a high-risk group when serologic tests became available in the 1990s. Their high prevalence initially reflected substantial transfusion exposure, but several observations supported ongoing nosocomial transmission within dialysis units: prevalence correlated with time on dialysis independently of transfusion burden, was higher in hemodialysis than in peritoneal dialysis or home hemodialysis, and remained substantial among patients who had never been transfused.

Improved blood-donor screening and the widespread use of erythropoietin reduced the transfusion contribution. The estimated post-transfusion hepatitis C risk fell from about 0.5% per blood unit in the 1980s to approximately 0.0001%, or one case per million units, in the United States. Attention therefore shifted toward infection-control practices within hemodialysis units. In long-term dialysis, HCV-related liver disease is often asymptomatic, and symptoms such as fatigue or cognitive impairment are difficult to attribute because they are common even without HCV. Cirrhosis remains infrequent in Western dialysis registries, at roughly 1.5–2%, but biochemical abnormalities and extrahepatic consequences still matter.

HCV also affects the experience of dialysis. In a study of 165 regularly dialyzed patients, 83 of whom were anti-HCV positive, HCV-positive status was independently associated with a lower mental component score on the SF-36 quality-of-life instrument, while no association with the physical component score was observed. Depression, diagnostic labeling, fatigue, cognitive impairment, and the burdens of hemodialysis may converge to reduce mental quality of life. Whether antiviral therapy lowers mortality through improvement in quality of life, even when liver histology or virologic markers do not change, remains uncertain.

For kidney transplant candidates, chronic HCV infection has been reported in 7–40% of recipients before transplantation, with variation by geography and demographic characteristics. Risk rises with longer end-stage renal disease, prior transplantation, black race, hepatitis B virus coinfection, and previous substance abuse; diabetes mellitus is also common, affecting about 30% of HCV-infected candidates aged 30–50 years and 63% of elderly candidates. Up to one quarter of candidates with active HCV infection have advanced fibrosis on liver biopsy despite compensated liver disease and no obvious clinical suspicion.

This hidden hepatic burden makes systematic screening essential. In regions with low HCV prevalence, initial testing should use an enzyme immunoassay followed by nucleic acid testing to confirm viremia in antibody-positive patients. In high-prevalence settings, nucleic acid testing should be the first-line test because a negative antibody assay cannot reliably exclude infection. The same insistence on separating exposure from active infection is crucial when evaluating transplant eligibility and planning treatment.

HCV is an independent risk factor for renal-allograft loss, although part of the effect may reflect the high immunologic risk of a population that often includes retransplant recipients and people with prolonged renal disease. HCV has been associated with glomerulitis and transplant glomerulopathy, lesions linked to anti-HLA antibodies and antibody-mediated rejection. At the same time, HCV itself is connected with autoimmunity and immune-complex injury, so immunologic confounding does not eliminate a direct pathogenic role.

HCV-infected renal and liver allograft recipients can develop immune-complex-mediated glomerulonephritis. Post-transplant proteinuria is a major clinical signal, and de novo membranoproliferative glomerulonephritis has been described in HCV-infected renal allografts. Later observations identified type II mixed cryoglobulinemia with IgM-kappa monoclonal components in patients with de novo glomerulonephritis. Cryocrit levels are often below 5% in allograft recipients, which can make cryoglobulins difficult to detect and characterize, while HCV RNA may be much more concentrated in the cryocrit than in serum, supporting a pathogenic role for the virus.

The allograft presentation may include hypertension, microhematuria, proteinuria, renal dysfunction, and occasionally nephrotic syndrome. Biopsy can show mesangial proliferation, double contours, and parietal IgM and C3 deposits, with variable chronic damage throughout the kidney. Electron microscopy may be required to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy: membranoproliferative disease produces subendothelial electron-dense deposits, whereas transplant glomerulopathy produces radiolucent areas in the glomerular basement membrane. The two lesions can coexist, expressing the combined force of humoral immunity and HCV-associated autoimmunity. Membranous glomerulonephritis has also been reported in HCV-infected allografts, usually with nephrotic syndrome, although a clear HCV-related mechanism is often absent.

Treatment and Significance

The relationship between HCV and CKD makes antiviral therapy part of renal as well as hepatic care. In the treatment framework described for 2011, pegylated interferon and ribavirin produced sustained virologic response in more than half of patients with chronic HCV infection, and sustained response represented virologic recovery with fibrosis remodeling when liver comorbidities were absent. Direct-acting antiviral drugs were developed to target viral enzymes, including protease and polymerase inhibitors, with broader-spectrum targets also under investigation. First-generation telaprevir- and boceprevir-based triple therapy increased sustained response rates by roughly 20–30% in genotype 1 infection, although safety, anemia, rash, cost, adherence, resistance, and drug interactions limited its use.

For CKD, the decisive clinical lesson is that HCV cannot be managed through liver tests alone. A patient may have mild liver-enzyme abnormalities or compensated liver disease while already carrying substantial fibrosis, proteinuria, immune-complex injury, or a heightened risk of renal decline. Conversely, antibody positivity without HCV RNA does not establish active infection. The concept therefore joins epidemiology, molecular diagnosis, renal surveillance, biopsy, infection control, dialysis practice, transplant assessment, and antiviral treatment into one continuum: identify active virus, measure both hepatic and renal damage, detect glomerular disease early, and account for the consequences of infection across the life of the kidney.